Arcturus therapeutics announces second quarter 2023 financial update and pipeline progress

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company,” “arcturus,” nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter and six months ended june 30, 2023 and provided corporate updates. “arcturus has continued to achieve significant operational progress alongside our e.
ARCT Ratings Summary
ARCT Quant Ranking